$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414048899 Filed on August 12, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q4
Revenue	$3.426K	$9.875K	$50.00K
YoY Change	-95.53%	-96.97%	-50.0%
Cost Of Revenue	$0.00	$0.00	$30.00K
YoY Change	-100.0%	-100.0%	200.0%
Gross Profit	$3.426K	$9.875K	$20.00K
YoY Change	-93.24%	-90.5%	-77.78%
Gross Profit Margin	100.0%	100.0%	40.0%
Selling, General & Admin	$2.326M	$2.686M	$2.250M
YoY Change	-28.03%	7.54%	69.17%
% of Gross Profit	67878.34%	27196.36%	11250.0%
Research & Development	$923.2K	$510.8K	$370.0K
YoY Change	187.49%	168.89%	-21.28%
% of Gross Profit	26945.97%	5172.32%	1850.0%
Depreciation & Amortization	$24.64K	$19.86K	$120.0K
YoY Change	-9.28%	-35.23%	20.0%
% of Gross Profit	719.29%	201.15%	600.0%
Operating Expenses	$3.249M	$3.196M	$2.630M
YoY Change	-8.55%	18.95%	46.93%
Operating Profit	-$3.245M	-$3.187M	-$2.610M
YoY Change	-7.33%	23.35%	53.53%
Interest Expense	$151.00	$1.443K	$0.00
YoY Change	15000.0%	309.94%
% of Operating Profit
Other Income/Expense, Net	-$140.00	-$1.443K
YoY Change
Pretax Income	-$3.245M	-$3.188M	-$2.760M
YoY Change	-7.32%	23.39%	61.4%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.245M	-$3.188M	-$2.760M
YoY Change	-7.32%	23.39%	61.4%
Net Earnings / Revenue	-94728.4%	-32283.3%	-5520.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$23.21M	-$22.79M	-$27.60M
COMMON SHARES
Basic Shares Outstanding	24.56M shares	24.43M shares	18.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.40M	$14.30M	$6.300M
YoY Change	48.05%	495.83%	270.59%
Cash & Equivalents	$11.37M	$14.30M	$6.342M
Short-Term Investments
Other Short-Term Assets	$300.0K	$300.0K	$300.0K
YoY Change	-50.0%	-86.96%	200.0%
Inventory	$0.00	$1.910K	$0.00
Prepaid Expenses			$932.6K
Receivables	$0.00	$0.00	$139.1K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.70M	$14.70M	$6.762M
YoY Change	36.12%	174.5%	239.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$200.0K	$127.7K	$163.1K
YoY Change	-54.88%	-37.93%	1.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$600.0K	$36.45K
YoY Change	-88.75%	-86.65%	-99.22%
Total Long-Term Assets	$5.100M	$5.119M	$5.247M
YoY Change	4.36%	8.92%	8.49%
TOTAL ASSETS
Total Short-Term Assets	$11.70M	$14.70M	$6.762M
Total Long-Term Assets	$5.100M	$5.119M	$5.247M
Total Assets	$16.80M	$19.82M	$12.01M
YoY Change	24.61%	97.11%	75.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$400.0K	$790.2K	$248.1K
YoY Change	1184.89%	329.44%	263.75%
Accrued Expenses	$393.7K	$226.6K	$295.3K
YoY Change	-71.88%	-85.46%	-81.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.500M	$1.563M	$1.402M
YoY Change	-22.77%	-11.87%	-15.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.500M	$1.563M	$1.402M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.500M	$1.600M	$1.407M
YoY Change	-21.05%	-11.11%	-17.21%
SHAREHOLDERS EQUITY
Retained Earnings		-$26.12M	-$20.52M
YoY Change		83.18%	110.82%
Common Stock		$24.44K	$18.57K
YoY Change		59.37%	43.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.20M	$18.26M	$10.60M
YoY Change
Total Liabilities & Shareholders Equity	$16.80M	$19.82M	$12.01M
YoY Change	24.61%	97.11%	75.93%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q4
OPERATING ACTIVITIES
Net Income	-$3.245M	-$3.188M	-$2.760M
YoY Change	-7.32%	23.39%	61.4%
Depreciation, Depletion And Amortization	$24.64K	$19.86K	$120.0K
YoY Change	-9.28%	-35.23%	20.0%
Cash From Operating Activities	-$2.980M	-$2.260M	-$2.650M
YoY Change	8.76%	7.11%	37.31%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$90.00K	-$90.00K
YoY Change	-67.74%	12.5%	-30.77%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$100.0K	-$90.00K	-$90.00K
YoY Change	-67.74%	12.5%	-30.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	150.0K	50.00K	1.390M
YoY Change	-98.19%	-98.46%	-58.75%
NET CHANGE
Cash From Operating Activities	-2.980M	-2.260M	-2.650M
Cash From Investing Activities	-100.0K	-90.00K	-90.00K
Cash From Financing Activities	150.0K	50.00K	1.390M
Net Change In Cash	-2.930M	-2.300M	-1.350M
YoY Change	-155.81%	-316.98%	-203.05%
FREE CASH FLOW
Cash From Operating Activities	-$2.980M	-$2.260M	-$2.650M
Capital Expenditures	-$100.0K	-$90.00K	-$90.00K
Free Cash Flow	-$2.880M	-$2.170M	-$2.560M
YoY Change	18.52%	6.9%	42.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127741	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1407396	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	18574	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	44347281	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31099691	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4622	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	23649	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	18255604	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	10601651	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19819098	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12009047	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163147	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	61309	USD
CY2013Q4	us-gaap	Security Deposit SecurityDeposit	36446	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4454185	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1228233	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	219030	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	205590	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	508748	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	33999	USD
CY2014Q2	us-gaap	Assets Assets	19819098	USD
CY2013Q4	us-gaap	Assets Assets	12009047	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	790184	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	248142	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	226642	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	399478	USD
CY2014Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21372	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	48157	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	508646	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	476477	USD
CY2014Q2	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	12028	USD
CY2013Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	211493	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1563494	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	24444	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26116121	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20516614	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Use of Estimates:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24444058	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18574334	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24444058	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18574334	shares
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	400000	USD
CY2014Q2	us-gaap	Supplies Supplies	36876	USD
CY2013Q4	us-gaap	Supplies Supplies	131204	USD
CY2014Q2	us-gaap	Prepaid Insurance PrepaidInsurance	89970	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	112517	USD
CY2014Q2	us-gaap	Deposit Assets DepositAssets	29500	USD
CY2013Q4	us-gaap	Deposit Assets DepositAssets	36906	USD
CY2014Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	16000	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	USD
CY2014Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	347453	USD
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	326824	USD
CY2014Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2014Q2	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	0	USD
CY2013Q4	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	15000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	155085	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114050	USD
CY2014Q2	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	158292	USD
CY2013Q4	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	158292	USD
	us-gaap	Depreciation Depreciation	35536	USD
	us-gaap	Depreciation Depreciation	41035	USD
CY2013Q2	us-gaap	Depreciation Depreciation	30668	USD
CY2014Q2	us-gaap	Depreciation Depreciation	19864	USD
CY2014Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4794853	USD
CY2013Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4794853	USD
CY2014Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	200000	USD
CY2013Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	0	USD
CY2014Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	176280	USD
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	105839	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	716948	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	505059	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	212137	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	435692	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	428431	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	411600	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	393990	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2572335	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	289718	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	33999	USD
CY2013Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	120488	USD
CY2014Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	9875	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	326078	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9875	USD
	us-gaap	Cost Of Services CostOfServices	49955	USD
	us-gaap	Cost Of Services CostOfServices	0	USD
CY2013Q2	us-gaap	Cost Of Services CostOfServices	2356	USD
CY2014Q2	us-gaap	Cost Of Services CostOfServices	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	238669	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	219804	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	222160	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Gross Profit GrossProfit	220124	USD
	us-gaap	Gross Profit GrossProfit	33999	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	103918	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	9875	USD
	us-gaap	Selling Expense SellingExpense	591965	USD
	us-gaap	Selling Expense SellingExpense	461223	USD
CY2013Q2	us-gaap	Selling Expense SellingExpense	319390	USD
CY2014Q2	us-gaap	Selling Expense SellingExpense	223385	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	410147	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	933270	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	189955	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	510767	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3742792	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4236964	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2177920	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2462256	USD
	us-gaap	Operating Expenses OperatingExpenses	4744904	USD
	us-gaap	Operating Expenses OperatingExpenses	5631457	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	2687265	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	3196408	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4524780	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5597458	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2583347	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3186533	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	143	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Interest Expense InterestExpense	359	USD
	us-gaap	Interest Expense InterestExpense	2192	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	352	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	1443	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4525139	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5599507	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2583699	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3187976	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4525139	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5599507	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-2583699	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-3187976	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14120962	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23515576	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14808728	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24430346	shares
CY2014Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	410449	USD
CY2013Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	408362	USD
CY2014Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	85457	USD
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	48232	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	464771	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	105894	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2014Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	12740	USD
CY2013Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	19883	USD
CY2014Q2	atos	Total Shares Authorized TotalSharesAuthorized	85000000	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6033426	shares
CY2014Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	14048491	USD
CY2013Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6092161	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	177561	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	480007	USD
CY2014Q2	atos	Recall Expenses Actual RecallExpensesActual	390812	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2282719	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1436669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	69236	shares
	atos	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	40000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3610152	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1413969	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3326450	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.43
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.64
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.25
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.28
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.50
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M17D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M19D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	561650	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	88150	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	508716	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	22728	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	24510	shares
CY2014Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	50000	USD
CY2013Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	50000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1011820	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	397715	USD
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	737309	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	167534	USD
	us-gaap	Profit Loss ProfitLoss	-4525139	USD
	us-gaap	Profit Loss ProfitLoss	-5599507	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	-181798	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	20323	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	226643	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	378759	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26158	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20323	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1910	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	36526	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	129719	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-47500	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-24863	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16822	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	542042	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-11123	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	32169	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	72537	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-26785	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	47327	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	252924	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	64759	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-172836	USD
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	0	USD
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	-199465	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	31654	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-19027	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3444090	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4858345	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	81370	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	20629	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	8500	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	170441	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-89870	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-191070	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	4248275	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13005745	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4248275	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13005745	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	714315	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7956330	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1725197	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2439512	USD
	us-gaap	Interest Paid InterestPaid	359	USD
	us-gaap	Interest Paid InterestPaid	2192	USD
	atos	Non Cash Reclassification Of Furniture And Equipment To Prepaid Expenses NonCashReclassificationOfFurnitureAndEquipmentToPrepaidExpenses	0	USD
	atos	Non Cash Reclassification Of Furniture And Equipment To Prepaid Expenses NonCashReclassificationOfFurnitureAndEquipmentToPrepaidExpenses	15000	USD
	atos	Common Stock Issued For Commitment Fee In Stock Purchase Agreement CommonStockIssuedForCommitmentFeeInStockPurchaseAgreement	2387250	USD
	atos	Common Stock Issued For Commitment Fee In Stock Purchase Agreement CommonStockIssuedForCommitmentFeeInStockPurchaseAgreement	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>NOTE 1: NATURE OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was initially formed to develop and market the Mammary Aspirate Specimen Cytology Test System, a modified breast pump, which is a medical device that collects specimens of nipple aspirate fluid (NAF).   The current version of the medical device is called the ForeCYTE Breast Aspirator.  The Company’s fiscal year ends on December 31st.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In December 2011, the Company established The National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory which performs our NAF cytology testing on NAF specimens including those collected with our breast aspirator. The NRLBH is developing other tests such as the ArgusCYTE test, NextCYTE test and FullCYTE test.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included intellectual property rights related to the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font>. <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> No liabilities were assumed by Atossa and Atossa assumed no future financial obligations. In consideration for the assets, Atossa provided the following consideration to the shareholders of Acueity:  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 862,500</font> shares of common stock, valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share, and warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 325,000</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share, valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.3457</font> per warrant, using a Black-Scholes-Merton Valuation Technique.</font> The acquired patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.00
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ATOSSA GENETICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001488039
CY2013Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ATOS
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24564058	shares
CY2014Q2	us-gaap	Inventory Net InventoryNet	1910	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2014Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	501961	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	651961	USD
CY2014Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	153000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	195977	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	94920	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13882	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	94921	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y25D
CY2014Q2	atos	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.020	pure
CY2014Q2	atos	Entitled To Receive Worth Of Common Stock EntitledToReceiveWorthOfCommonStock	30.00
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	282063	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14400	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	450	USD
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	14002162	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	397715	USD
	atos	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	32000	USD
	atos	Financing Fee From Public Offerig FinancingFeeFromPublicOfferig	-1078417	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Reclassification:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The prior period deferred financing costs have been reclassified to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Certain prior period accrued expenses have been reclassified as accounts payable to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	862500	shares
CY2012Q3	us-gaap	Share Price SharePrice	5.00
	atos	Warrants Issued During Period Acquisitions WarrantsIssuedDuringPeriodAcquisitions	325000	shares
	atos	Warrant Price WarrantPrice	2.3457
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	150000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	50000	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2196183	shares
CY2012Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1858544	USD
CY2014Q2	atos	Directors Compensation Paid DirectorsCompensationPaid	35000	USD

Files In Submission

Name	View Source	Status
0001144204-14-048899-index-headers.html	Edgar Link	pending
0001144204-14-048899-index.html	Edgar Link	pending
0001144204-14-048899.txt	Edgar Link	pending
0001144204-14-048899-xbrl.zip	Edgar Link	pending
atos-20140630.xml	Edgar Link	completed
atos-20140630.xsd	Edgar Link	pending
atos-20140630_cal.xml	Edgar Link	unprocessable
atos-20140630_def.xml	Edgar Link	unprocessable
atos-20140630_lab.xml	Edgar Link	unprocessable
atos-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg16.jpg	Edgar Link	pending
tsig1.jpg	Edgar Link	pending
tsig2.jpg	Edgar Link	pending
tsig3.jpg	Edgar Link	pending
tsig4.jpg	Edgar Link	pending
tstamp1.jpg	Edgar Link	pending
tstamp2.jpg	Edgar Link	pending
tstamp3.jpg	Edgar Link	pending
v385123_10-q.htm	Edgar Link	pending
v385123_ex10-1.htm	Edgar Link	pending
v385123_ex31-1.htm	Edgar Link	pending
v385123_ex31-2.htm	Edgar Link	pending
v385123_ex32-1.htm	Edgar Link	pending
v385123_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q3 Form 10-Q Financial Statement

#000114420414048899 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q3 Form 10-Q Financial Statement

#000114420414048899 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos